Table 6 Risk for tertiary individual CV endpoints with linagliptin versus total comparators based on Cox hazard model
Cox HR (95% CI) | |
|---|---|
CV death | 0.74 (0.10-5.33) |
Non-fatal MI | 0.52 (0.17-1.54) |
Non-fatal stroke | 0.11 (0.02-0.51) |
TIA | 0.17 (0.02-1.53) |
UAP with hospitalization | 0.24 (0.02-2.34) |
UAP without hospitalization | 0.73 (0.04-12.02) |
SAP | 1.06 (0.44-2.58) |
Total mortality | 1.02 (0.23-4.63) |